GCM1: A Promising Drug Target and Biomarker for Various Diseases

Target Name: GCM1

NCBI ID: G8521

GCM1

GCM1: A Promising Drug Target and Biomarker for Various Diseases

GCM1 (Guanosine-Conjugated Monoclonal antibody) is a drug target and a biomarker that has been gaining significant attention in the medical research field. GCM1 is a type of antibody that is derived from monoclonal antibodies, which means that it is produced from a single cell.

GCM1 has been shown to have potential as a drug target by targeting the alpha-helical critical region of the protein huntingtin, a protein that is known to play a role in various diseases, including neurodegenerative disorders, cancer, and autoimmune diseases.

Research has shown that GCM1 can effectively inhibit the activity of huntingtin, leading to a reduction in the growth of cancer cells and a decrease in the severity of neurodegenerative disorders. This suggests that GCM1 may be an effective drug target for treating these diseases.

In addition to its potential as a drug target, GCM1 has also been shown to be a valuable biomarker for various diseases. For example, GCM1 has been used to diagnose and monitor the progression of neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease.

The use of GCM1 as a biomarker has been shown to be effective in identifying the early stages of neurodegenerative disorders and evaluating the effectiveness of various treatments. This suggests that GCM1 may be a valuable tool for diagnosing and treating these diseases in the future.

GCM1 has also been shown to be effective in targeting cancer cells. Studies have shown that GCM1 can effectively inhibit the growth of cancer cells and trigger apoptosis, which is the process by which cancer cells die.

This suggests that GCM1 may be an effective drug target for treating various cancers, including breast, lung, and ovarian cancers.

In conclusion, GCM1 is a drug target and biomarker that has shown potential in treating a variety of diseases. Its ability to inhibit the activity of huntingtin and its potential as a diagnostic tool make it an attractive target for further research. As the research continues, GCM1 is likely to provide new insights into the treatment of various diseases and improve our overall understanding of the underlying causes of these conditions.

Protein Name: Glial Cells Missing Transcription Factor 1

Functions: Transcription factor involved in the control of expression of placental growth factor (PGF) and other placenta-specific genes (PubMed:10542267, PubMed:18160678). Binds to the trophoblast-specific element 2 (TSE2) of the aromatase gene enhancer (PubMed:10542267). Binds to the SYDE1 promoter (PubMed:27917469). Has a central role in mediating the differentiation of trophoblast cells along both the villous and extravillous pathways in placental development (PubMed:19219068)

The "GCM1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GCM1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets